ParmianiG., CastelliC., DalerbaP., MortariniR., RivoltiniL., MarincolaF.M., AnichiniA.: Immunotherapy of cancer with peptide-based vaccines: what have we achieved and where are we going?J Natl Cancer Inst USA, 94: 805–818, 2002.
2.
RenkvistN., CastelliC., RobbinsP.F., ParmianiG.: A listing of human tumor antigens recognized by T cells.Cancer Immunol Immunother, 50: 3–15, 2001.
3.
RivoltiniL., KawakamiY., SakaguchiK., SouthwoodS., SetteA., RobbinsP.F.: Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.J Immunol, 154: 2257–2265, 1995.
4.
AnichiniA., MollaA., MortariniR., TragniG., BersaniI., Di NicolaM.: An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.J Exp Med, 190: 651–667, 1999.
5.
GilboaE.: The makings of a tumor rejection antigen.Immunity, 11: 263–270, 1999.
6.
MateoL., GardnerJ., ChenQ., SchmidtC., DownM., ElliottS.L.: An HLA-A2 polyepitope vaccine for melanoma immunotherapy.J Immunol, 163: 4058–4063, 1999.
7.
GrohmannU., BianchiR., AyroldiE., BelladonnaM.L., SuraceD., FiorettiM.C.: A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state.J Immunol, 158: 3593–3602, 1997.
8.
MarchandM., van BarenN., WeynantsP., BrichardV., DrenoB., TessierM.H.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.Int J Cancer, 80: 219–230, 1999.
9.
GjertsenM.K., BuanesT., RosselandA.R., BakkaA., GladhaugI., SoreideO.: Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma.Int J Cancer, 92: 441–450, 2001.
10.
NestleF.O., AlijagicS., GillietM., SunY., GrabbeS., DummerR.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.Nature Med, 4: 328, 1998.
11.
BendandiM., GockeC.D., KobrinC.B., BenkoF.A., SternasL.A., PenningtonR.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.Nature Med, 10: 1171–1177, 1999.
12.
CastelliC., CiupituA-MT, RiniF., RivoltiniL., MazzocchiA., KiesslingR.: Human HSP70 peptide complexes specifically activate anti-melanoma T cells.Cancer Res, 61: 222–227, 2001.
13.
MarincolaF.M., JaffeE.M., HicklinD.J., FerroneS.Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance.Adv Immunol, 74: 181–273, 2000.
14.
RivoltiniL., RadrizzaniM., AccorneroP., SquarcinaP., ChiodoniC., MazzocchiA.: Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.J Immunol, 161: 1220–1230, 1998.
